-
公开(公告)号：US20240218051A1
公开(公告)日：2024-07-04
申请号：US18534085
申请日：2023-12-08
Applicant: GENZYME CORPORATION
Inventor： Qun Zhou , Sunghae Park , Huawei Qiu , Marie-Priscille Brun , Francis Duffieux
CPC classification number: C07K16/00 , A61K47/6803 , C07K2317/14 , C07K2317/52 , C07K2317/56 , C07K2317/94
Abstract: Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.
-
公开(公告)号：US11325970B2
公开(公告)日：2022-05-10
申请号：US15555500
申请日：2016-03-03
Applicant: GENZYME CORPORATION
Inventor： Huawei Qiu , Julie Bird
IPC: A61K39/395 , C07K16/22
Abstract: A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.
-
公开(公告)号：US20210024620A1
公开(公告)日：2021-01-28
申请号：US16938727
申请日：2020-07-24
Applicant: Genzyme Corporation
Inventor： Brian Mackness , Huawei Qiu
IPC: C07K16/18 , A61K39/395 , A61K51/10
Abstract: The present disclosure provides methods of treating an antibody-mediated disorder (e.g., an autoimmune disease) using an FcRn antagonist, e.g., a binding polypeptide (e.g., an antibody and/or an immunoadhesin), comprising a modified Fc domain. The present disclosure also provides methods of enhancing diagnostic imaging using an FcRn antagonist disclosed herein. The present disclosure further provides methods of reducing exposure of normal tissue to a radiolabeled antibody during diagnostic imaging using an FcRn antagonist disclosed herein. Methods comprising administering to a subject a therapeutically effective amount of an FcRn antagonist disclosed herein are also provided.
-
公开(公告)号：US10214589B2
公开(公告)日：2019-02-26
申请号：US15417648
申请日：2017-01-27
Applicant: Genzyme Corporation
Inventor： Clark Pan , Qun Zhou , James Stefano , Pradeep Dhal , Bo Chen , Diego Gianolio , Robert Miller , Huawei Qiu
Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
公开(公告)号：US09790268B2
公开(公告)日：2017-10-17
申请号：US14205264
申请日：2014-03-11
Applicant: Genzyme Corporation
Inventor： Clark Pan , Huawei Qiu
CPC classification number: C07K16/18 , A61K47/6803 , A61K47/6811 , A61K47/6851 , A61K47/6889 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K16/00 , C07K16/2809 , C07K16/2851 , C07K16/2893 , C07K16/32 , C07K16/40 , C07K2317/41 , C07K2317/52 , C07K2317/522 , C07K2317/71 , C07K2317/73
Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20240343790A1
公开(公告)日：2024-10-17
申请号：US18627131
申请日：2024-04-04
Applicant: Genzyme Corporation
Inventor： Huawei Qiu , Clark Pan , Julie Bird
CPC classification number: C07K16/22 , A61K39/395 , A61K39/3955 , C07K16/00 , C07K16/46 , C12N15/11 , C12N15/62 , A61K2039/505 , C07K2317/21 , C07K2317/35 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/64 , C07K2317/70 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/23 , C07K2319/73
Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
-
公开(公告)号：US11807690B2
公开(公告)日：2023-11-07
申请号：US16655500
申请日：2019-10-17
Applicant: Genzyme Corporation
Inventor： Clark Pan , Huawei Qiu , Pradeep Dhal , Bo Chen , Diego Gianolio
CPC classification number: C07K16/2893 , A61K47/549 , A61K47/6803 , A61K47/6869 , A61K47/6889 , C07K16/28 , C07K16/2809 , C07K16/2851 , C07K16/32 , C07K16/40 , C07K2317/40 , C07K2317/41 , C07K2317/522 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
公开(公告)号：US20220363740A1
公开(公告)日：2022-11-17
申请号：US17713087
申请日：2022-04-04
Applicant: GENZYME CORPORATION
Inventor： Huawei Qiu , Clark Pan , Julie Bird
Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
-
公开(公告)号：US10508146B2
公开(公告)日：2019-12-17
申请号：US15555499
申请日：2016-03-03
Applicant: GENZYME CORPORATION
Inventor： Huawei Qiu , Clark Pan , Julie Bird
IPC: A61K39/395 , C07K16/22 , C07K16/46 , C07K16/00 , A61K39/00
Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
-
公开(公告)号：US20180208650A1
公开(公告)日：2018-07-26
申请号：US15875125
申请日：2018-01-19
Applicant: Genzyme Corporation
Inventor： Huawei Qiu , Sunghae Park , James Stefano
CPC classification number: C07K16/22 , A61K47/68 , A61K2039/505 , A61P13/12 , A61P19/08 , A61P19/10 , A61P35/04 , C07K7/06 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
-
-
-
-
-
-
-
-
-
Search Results
45
records
(took 0.021 seconds)
